$181.00 - $181.00
[D-Arg1,D-Trp5,7,9,Leu11]-Substance P is a heavily modified full-length Substance P analog containing D-Arg1, three D-Trp substitutions and a C-terminal Leu11 replacement.
Unlike a receptor-subtype-selective NK1 antagonist, this peptide has been studied as a broad-spectrum neuropeptide antagonist capable of interfering with signaling initiated by several peptide growth factors.
Product Information
| Product Name | [D-Arg1,D-Trp5,7,9,Leu11]-Substance P |
| Catalog No. | AS2541 |
| CAS No. | 122481-75-8 |
| Sequence | D-Arg-Pro-Lys-Pro-D-Trp-Gln-D-Trp-Phe-D-Trp-Leu-Leu-NH2 |
| Peptide Length | 11 residues |
| Molecular Formula | C81H110N20O12 |
| Molecular Weight | Approximately 1555.9 Da |
| Key Modifications | D-Arg1; D-Trp5; D-Trp7; D-Trp9; Leu11 |
| Research Profile | Broad-spectrum neuropeptide signaling antagonist |
Broad-Spectrum Signal Inhibition
This analog was identified during studies of neuropeptide-driven growth signaling in small cell lung cancer. It inhibited proliferation of H-510 and H-69 SCLC cells with a reported IC50 of approximately 5 μM.
The peptide also inhibited neuropeptide-induced Ca2+ mobilization and MAP kinase activation in experimental systems stimulated by ligands including vasopressin and bradykinin.
This profile is important experimentally because the peptide should not be interpreted simply as an NK1-selective inhibitor. Its activity can extend across signaling pathways initiated by structurally unrelated neuropeptides.
Why the D-Trp Pattern Matters
D-Trp residues at positions 5, 7 and 9 introduce bulky aromatic side chains with reversed stereochemistry. These modifications can change recognition across several peptide-responsive GPCR systems.
We recommend this analog when the experimental question concerns broad neuropeptide-dependent signaling rather than selective blockade of a single tachykinin receptor.
Research Applications
The peptide can support broad-spectrum neuropeptide signaling studies, SCLC research models, Ca2+ mobilization experiments, MAPK signaling studies and peptide antagonist SAR.
Frequently Asked Questions
Is this peptide selective for NK1?
No. Published studies describe broader inhibition of signaling initiated by several neuropeptides.
What growth inhibition has been reported?
An IC50 of approximately 5 μM was reported for inhibition of H-510 and H-69 small cell lung cancer cell proliferation.
Does it contain methionine?
No. Met11 is replaced by Leu.